Applied InSilico Ltd. Announces its First Top Five Pharmaceutical Customer; GlaxoSmithKline Licenses ELE(tm) Evolutionary Learning Environment.

CHIPPENHAM, United Kingdom -- Applied InSilico, a provider of analytical solutions for drug discovery and development, today announced that GlaxoSmithKline (GSK) has signed a multi-year agreement for its ELE(tm) (Evolutionary Learning Environment) software platform. Financial details were not disclosed.

ELE(tm) is an advanced evolutionary learning and computation system that helps scientists in their quest to find new insights into complex diseases. It uses a true parallel distributed architecture to allow detailed analysis of very large and complex datasets and higher throughput of smaller problem datasets.

GSK will integrate ELE(tm) into a new global decision support environment for library design, model building and selection of drug candidates. ELE(tm) will provide advanced and automated data analysis and modelling capabilities and will be able to instantly deploy predictive models to scientists throughout the organization through its web services and third-party applications.

Jay Perrett, CTO of Applied InSilico said, "ELE(tm) is capable of simultaneously analyzing complex life science data to provide insight into derived models. The resulting models are rapidly deployed and updated in a simple point and click environment. My team is extremely pleased to have the opportunity to work closely with GSK and their collaborators as we integrate ELE(tm) into their systems."

Clive Briant, VP Business Development of Applied InSilico commented, "This is a major order that came after working closely with GSK scientists and developers during an extensive evaluation. Their decision represents a significant step forward for Applied InSilico, and further validates how our in silico modelling platform fits into a large pharmaceutical environment."

About Applied InSilico

Founded in 2003, Applied InSilico dramatically reduces time and resources during drug discovery and development by providing uncompromised insight into complex disease data. Their ELE(tm) technology reveals verifiable relationships in the most complex of datasets in such areas as ADMET, genomics, proteomics, metabolomics research, and provides a holistic approach across the complete drug discovery pipeline. For more information, visit www.appliedinsilico.com.